title: [Kawasaki disease in newborns and infants: refractory forms to immunoglobulin therapy].
abstract: We studied 52 consecutive patients with Kawasaki disease hospitalized (1984 -2003) during the acute phase (mean age 2.5 + 2.4 years; range 0.3 to 16 years, 34 males, 18 cases with coronary aneurysms, median follow-up 6.7 years), and identified a subgroup presenting a refractory subtype to immunoglobulin therapy.
  
  
  RESULTS
  forty-nine infants benefited from a first regimen of immunoglobulins, 8.4 + 6 days following the onset of symptoms. Eleven infants (1.4 + 1.2 years, range 0.3 - 4.3 years, median 1.7 years) were non-responders, with coronary aneurysms in 8 cases (giant aneurysms (>8 mm) in 4 cases). These 11 infants were treated a second time by immunoglobulins, but 6 cases (1.8 + 1.6 years, with two cases of severe ventricular dysfunction and 2 cases of fatal myocardial infarction) required an additive therapy with (oral or IV route) corticosteroids (2) and cyclophosphamide bolus (4) with or without repetitive plasmapheresis (4). Non-responder patients had their treatment onset later (p<0.0003) using higher dosages (p<0.005), a longer delay for fever or biological signs correction (p<0.02), a worsening of coronary lesions (p<0.05) with more coronary secondary aneurysms (p<.005). The aneurysms, more frequent at the second phase of the disease (p<0.0001) are associated with: a younger age (p<0.03), a lower weight (p<0.02), a later onset of treatment (p<0.03), prolonged fever or inflammatory syndrome (p<0.05), higher level of fibrinogene (p<0.02). The overall mortality (5.7%) is correlated with giant aneurysms (p<0.001), myocardial ischemia (p<0.0001), heart failure (p<0.0001), and lack of early response to treatment (p<0.003).
  
  
  CONCLUSIONS
  immunoglobin therapy can be repeated. In case of severe forms, the use of corticosteroids, cyclophosphamide and plasmapheresis may be proposed.
authors.affiliation: Service de cardiologie pédiatrique, hôpital d'enfants, CHU de Brabois, Vandoeuvre-lès-Nancy. h.lucron@chu-nancy.fr
authors.forename: H
authors.initials: H
authors.lastname: Lucron
authors.forename: G
authors.initials: G
authors.lastname: Bosser
authors.forename: J P
authors.initials: JP
authors.lastname: Lethor
authors.forename: D
authors.initials: D
authors.lastname: Sommelet
authors.forename: F
authors.initials: F
authors.lastname: Feillet
authors.forename: G
authors.initials: G
authors.lastname: Burger
authors.forename: P
authors.initials: P
authors.lastname: Monin
authors.forename: F
authors.initials: F
authors.lastname: Marçon
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007136:Immunoglobulins / Q000627:therapeutic use*; D007223:Infant; D008297:Male; D009080:Mucocutaneous Lymph Node Syndrome / Q000188:drug therapy*; D012189:Retrospective Studies
chemical_list: D007136:Immunoglobulins